TranslatePriority 1 from the mitochondrial disease PSP
| UNCERTAINTY: Could an understanding of the cellular and molecular processes in mitochondrial disease lead to new treatments? (JLA PSP Priority 1) | |
|---|---|
| Overall ranking | 1 |
| JLA question ID | 0095/1 |
| Explanatory note | Not available |
| Evidence | |
| Health Research Classification System category |
Metabolic and Endocrine
|
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Can we develop new drugs that target fundamental defects across a range of mitochondrial diseases? ~ What kind if treatments could interfere with the basic mechanisms of cell dysfunction and disease progression over time to delay, stop or reverse tissue dysfunction? |
| Submitted by | Healthcare Professional x 1 |
| PSP information | |
|---|---|
| PSP unique ID | 0095 |
| PSP name | Mitochondrial Disease |
| Total number of uncertainties identified by this PSP. | 42 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 19 January 2020 |
